This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
VLDLR · Western blot design guide
VLDLR Western Blot Planning Guide
Plan a VLDLR Western blot around the catalog-observed 96.1 kDa band, image-backed A02195-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
VLDLR Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 96.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Cerebellum | |
| Negative control | Lymph node |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 96.1 kDa |
| ⓘ | Localization | Cell membrane / Membrane, clathrin-coated pit |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated VLDLR Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A02195-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected VLDLR Western Blot Band Size?
Use the product-observed 96.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 96.1 kDa | Matches the authoritative product WB observation. |
| 96.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected VLDLR appearancePlan around 96.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 96.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 96.1 kDa from UniProt P98155; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A02195-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 96.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing VLDLR band
A02195-1 · VLDLR
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for VLDLR Western blot
🧪Use Cerebellum as the first positive-control candidate and Lymph node as the HPA Not detected negative candidate.
Positive control: Cerebellum (Medium)
Negative control: Lymph node (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for VLDLR
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Caudate | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced VLDLR Western Blot Tips
Deeper troubleshooting and optimisation questions for VLDLR, answered from its protein features.
Which band should guide the blot?
Use 96.1 kDa, the observation attached to the authoritative A02195-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 96.1 kDa expectation.
Which positive control should I start with?
Start with Cerebellum, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Lymph node as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for VLDLR Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A02195-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC2988033, PMC11134955, PMC4580245.
Boster reagents
VLDLR Western Blot Reagents
Human/Mouse/Rat-reactive VLDLR Western blot reagents with authoritative product imagery.
Real WB data
Anti-VLDL Receptor/VLDLR Antibody Picoband®
Cat # A02195-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P98155
- Human Protein Atlas — VLDLR
- A02195-1 product record
- PMC2988033 — Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers.
- PMC11134955 — SIRT1 regulates hepatic vldlr levels.
- PMC4580245 — Very low density lipoprotein receptor regulates dendritic spine formation in a RasGRF1/CaMKII dependent manner.